In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US […]readmore
Tags : Prostate Cancer
Shots: The approval is based on data from 2 pivotal studies i.e OSPREY & CONDOR evaluating the safety & diagnostic performance of Pylarify in patients with prostate cancer Results: 1st […]readmore
In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test […]readmore
Shots: The approval is based on two prospective studies assessing Ga 68 PSMA-11 in 960 men with prostate cancer. The first trial enrolled 325 patients & the second trial enrolled […]readmore
Shots: The P-III PROfound study involves assessing of Lynparza vs enzalutamide or abiraterone in patients with mCRPC, progressed on prior treatment with NHA treatments (abiraterone or enzalutamide) along with tumor […]readmore
Shots: Janssen and Resolution Bioscience develops Resolution’s HRD liquid biopsy test as a companion diagnostic for Janssen’s Niraparib, being investigated for the treatment of metastatic castration-resistant prostate cancer The Resolution […]readmore
Shots: Progenics to receive royalties on sales of 1404 in EU. ROTOP to get an exclusive license to develop & commercialize 1404 in EU and is also responsible for regulatory […]readmore